JP Nadda releases 10th edition of Indian Pharmacopoeia 2026, strengthening India’s drug quality standards.
Photo Credit: PIB
New Delhi, January 2, 2026: Union Minister of Health and Family Welfare and Chemicals and Fertilizers JP Nadda on Friday released the 10th edition of the Indian Pharmacopoeia (IP) 2026, the official book of drug standards in India, at the Dr. Ambedkar International Centre, New Delhi.
The new edition reflects India’s sustained commitment to enhancing the quality, safety, and efficacy of medicines.
Addressing the gathering, JP Nadda said that the Indian Pharmacopoeia serves as the foundation of India’s pharmaceutical regulatory framework.
He noted that the 10th edition incorporates scientific advancements, global best practices, and India’s growing leadership in pharmaceuticals and regulation.
JP Nadda emphasized the expanded coverage and new standards:
The Union Health Minister informed that the Indian Pharmacopoeia 2026 includes 121 new monographs, taking the total number to 3,340 monographs.
JP Nadda said that coverage has been significantly areas such as anti-tuberculosis, anti-diabetic, and anti-cancer drugs, along with iron supplements, ensuring comprehensive standardization of medicines used under various national health programs.
Global recognition and health diplomacy:
Highlighting India’s growing global role, JP Nadda said that the standards of the Indian Pharmacopoeia have gained international acceptance and have become a key component of India’s health diplomacy.
“The Indian Pharmacopoeia is now recognized in 19 countries of the global south,” he said.
The minister also underlined the remarkable progress of India’s Pharmacovigilance Program of India (PvPI) under the Indian Pharmacopoeia Commission (IPC).
He noted that while India ranked 123rd globally in contributions to the World Health Organization’s pharmacovigilance database during 2009-2014, it has now risen to 8th position in 2025.
Praising the IPC and PvPI teams, JP Nadda said this achievement reflects India’s strong commitment to patient safety, quality assurance, and effective regulatory oversight.
JP Nadda highlighted that for the first time, the Indian Pharmacopoeia 2026 includes 20 blood component monographs related to blood transfusion therapy, in line with the Drugs and Cosmetics (Second Amendment) rules, 2020.
This marks a significant step towards improving standards in transfusion medicine.
The Union Minister said that under the visionary leadership of Prime Minister Narendra Modi, the government has consistently worked to strengthen healthcare systems and regulatory institutions.
He emphasized that Indian Pharmacopoeia 2026 reflects the government’s unwavering focus on quality, transparency, and public welfare, and congratulated the IPC and all stakeholders involved in bringing out the 10th edition.
On the occasion, Union Health Secretary Punnya Salila Srivastava described the publication of the Indian Pharmacopoeia 2026 as a major milestone in strengthening India’s drug regulatory mechanism.
She said that a robust, science-based pharmacopoeia is essential to ensure the availability of safe, effective, and quality-assured medicines.
She added that continuous updating and harmonization of standards demonstrates India’s commitment to global best practices, patient safety, and regulatory excellence, while supporting the country’s expanding role in the global pharmaceutical supply chain.
About the Indian Pharmacopoeia:
The Indian Pharmacopoeia (IP) is published by the Indian Pharmacopoeia Commission (IPC) on behalf of the Ministry of Health and Family Welfare, as mandated under the Drugs and Cosmetics Act 1940.
It sets official, legally enforceable standards for drugs manufactured or marketed in India and plays a crucial role in licensing, inspection, distribution, and overall quality assurance of medicines in the country.
As a member of the Pharmacopoeial Discussion Group (PDG), the Indian Pharmacopoeia (IP) is actively collaborating with the European Pharmacopoeia, Japanese Pharmacopoeia, and United States Pharmacopoeia to harmonize Indian Pharmacopoeia monographs and general chapters.
The general requirements of the Indian Pharmacopoeia have also been aligned with the standards of the International Council for Harmonisation (ICH).
This alignment further reinforces India’s commitment to globally harmonized, internationally accepted drug quality standards and strengthens confidence in Indian medicines worldwide.
Also Read: IIT Delhi comes under the 125 list of QS World University rankings 2026.
EOM.